| Date Time |
Speaker |
Topic |
Slider |
Video |
2021/9/23
2000-2100 |
Tapan Kadia
(MD Anderson Cancer Center, TX, USA) |
Redefining the standard of care: improving outcomes in AML ineligible for intensive chemotherapy |
Slider | Video |
2021/12/16
2100-2200 |
Courtney D. DiNardo
(MD Anderson Cancer Center, TX, USA) |
The use of novel agents in mutation subtypes of AML |
Slider | Video |
2022/3/24
2100-2200 |
Naval Daver
(MD Anderson Cancer Center, TX, USA) |
The challenging face of AML: FLT3 & IDH mutation and other high risk population- how to manage? |
Slider | Video |
2022/6/23
2100-2200 |
Daniel Pollyea
(UC Health, CO, USA) |
What have we learnt so far? Optimizing management of emerging therapies in AML |
Slider | Video |
2022/11/17
2100-2200 |
Lars Bullinger
(Charité - Universitätsmedizin Berlin, Germany) |
Highlights for MRD assessment in AML |
none | Video |
2023/5/11
2100-2200 |
Keith W. Pratz
University of Pennsylvania, USA |
Efficacy and Safety of Long-term Azacitidine and Venetoclax for AML |
Slider | Video |
中文
English